Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 28, 2023
Elicio Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(IRS Employer Identification No.)
451 D Street. 5th Floor
Boston, Massachusetts 02110
(Address of principal executive offices, including zip code )
(857) 209-0050
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
(Title of each class)(Trading Symbol)(Name of exchange on which registered)
Common Stock, $0.01 par value per shareELTXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 28, 2023, Assaf Segal submitted his resignation from the Board of Directors (the “Board”) of Elicio Therapeutics, Inc. (the “Company”), which resignation was effective immediately. Mr. Segal’s resignation from the Board follows his recently announced upcoming departure from his role as Chief Executive Officer at Clal Biotechnology Industries and was not the result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Elicio Therapeutics, Inc.
Date: August 30, 2023
Robert Connelly
President and Chief Executive Officer
(Principal Executive Officer)

Document and Entity Information Document
Aug. 10, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 28, 2023
Entity Registrant Name Elicio Therapeutics, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39990
Entity Tax Identification Number 11-3430072
Entity Address, Address Line One 451 D Street. 5th Floor
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02110
City Area Code 857
Local Phone Number 209-0050
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value per share
Trading Symbol ELTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001601485
Amendment Flag false

Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Jan 2024 to Feb 2024 Click Here for more Angion Biomedica Charts.
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Feb 2023 to Feb 2024 Click Here for more Angion Biomedica Charts.